WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
News & Events
Maps & Locations
PATIENT AND VISITOR INFORMATION
PREVENTION AND SCREENING
HOW TO HELP
FOR HEALTH PROFESSIONALS
Go back to:
Content Block Control
RETURN TO SEARCH RESULTS
A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754 (IND #75648) Versus Weekly Paclitaxel Plus Placebo In The Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma (NCI Ver 1/19/12)
You are being asked to take part in this study because you have ovarian, fallopian tube, or primary peritoneal cancer that has failed to respond to initial chemotherapies given to you or has re-grown after surgery, radiation therapy, or other forms of therapy.
The purpose of this study is to find out if the drugs elesclomol sodium and paclitaxel will work in treating your type of cancer and to find out what side effects are caused by treatment with this drug combination.
(Links will take you off this web site)
Internal Protocol Documents (requires Siteman administrative database password)
© 2009 All rights reserved